Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
DAIC
MARCH 7, 2024
Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% The CardiAMP HF II trial is expected to similarly secure CMS reimbursement. vs. 13.2%, respectively).
105 
Let's personalize your content